Update on biomarkers in neuromyelitis optica

GJCFICC&BR

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

Original languageEnglish (US)
Article numbere134
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Neuromyelitis Optica
Biomarkers
Aquaporin 4
Immunoglobulin G
Recurrence
Spinal Nerves
Optic Nerve
Nervous System
Autoimmune Diseases
Spinal Cord
Therapeutics
Clinical Trials
Antibodies
Serum

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Update on biomarkers in neuromyelitis optica. / GJCFICC&BR.

In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, No. 4, e134, 01.01.2015.

Research output: Contribution to journalReview article

@article{0ff202ec80394564b09191749de26dfe,
title = "Update on biomarkers in neuromyelitis optica",
abstract = "Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.",
author = "GJCFICC&BR and Esther Melamed and Michael Levy and Waters, {Patrick J.} and Sato, {Douglas Kazutoshi} and Bennett, {Jeffrey L.} and John, {Gareth R.} and Hooper, {Douglas C.} and Albert Saiz and Amit Bar-Or and Kim, {Ho Jin} and Lakha Pandit and Leite, {Maria Isabel} and Nasrin Asgari and Najib Kissani and Rogier Hintzen and Romain Marignier and Sven Jarius and John Marcelletti and Smith, {Terry J.} and Yeaman, {Michael R.} and Han, {May H.} and Orhan Aktas and Metha Apiwattanakul and Brenda Banwell and Bichuetti, {Denis Bernardi} and Broadley, {Simon A.} and Philippe Cabre and Tanuja Chitnis and {de S{\`e}ze}, J{\'e}r{\^o}me and Kazuo Fujihara and Benjamin Greenberg and Kerstin Hellwig and Raffaele Iorio and Klawiter, {Eric C.} and Ingo Kleiter and Lana-Peixoto, {Marco Aur{\'e}lio} and Hideyuki Nakashima and K. O'connor and Jackie Palace and Paul, {Friedman A.} and Naraporn Prayoonwiwat and Klemens Ruprecht and Olaf Stuve and Tedder, {Thomas F.} and Tenembaum, {Silvia N.} and Garrahan, {Juan P.} and Buenos Aires and {van Herle}, Katja and {van Pelt}, Danielle and Pablo Villoslada",
year = "2015",
month = "1",
day = "1",
doi = "10.1212/NXI.0000000000000134",
language = "English (US)",
volume = "2",
journal = "Neurology: Neuroimmunology and NeuroInflammation",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Update on biomarkers in neuromyelitis optica

AU - GJCFICC&BR

AU - Melamed, Esther

AU - Levy, Michael

AU - Waters, Patrick J.

AU - Sato, Douglas Kazutoshi

AU - Bennett, Jeffrey L.

AU - John, Gareth R.

AU - Hooper, Douglas C.

AU - Saiz, Albert

AU - Bar-Or, Amit

AU - Kim, Ho Jin

AU - Pandit, Lakha

AU - Leite, Maria Isabel

AU - Asgari, Nasrin

AU - Kissani, Najib

AU - Hintzen, Rogier

AU - Marignier, Romain

AU - Jarius, Sven

AU - Marcelletti, John

AU - Smith, Terry J.

AU - Yeaman, Michael R.

AU - Han, May H.

AU - Aktas, Orhan

AU - Apiwattanakul, Metha

AU - Banwell, Brenda

AU - Bichuetti, Denis Bernardi

AU - Broadley, Simon A.

AU - Cabre, Philippe

AU - Chitnis, Tanuja

AU - de Sèze, Jérôme

AU - Fujihara, Kazuo

AU - Greenberg, Benjamin

AU - Hellwig, Kerstin

AU - Iorio, Raffaele

AU - Klawiter, Eric C.

AU - Kleiter, Ingo

AU - Lana-Peixoto, Marco Aurélio

AU - Nakashima, Hideyuki

AU - O'connor, K.

AU - Palace, Jackie

AU - Paul, Friedman A.

AU - Prayoonwiwat, Naraporn

AU - Ruprecht, Klemens

AU - Stuve, Olaf

AU - Tedder, Thomas F.

AU - Tenembaum, Silvia N.

AU - Garrahan, Juan P.

AU - Aires, Buenos

AU - van Herle, Katja

AU - van Pelt, Danielle

AU - Villoslada, Pablo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

AB - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

UR - http://www.scopus.com/inward/record.url?scp=84969320801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969320801&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000134

DO - 10.1212/NXI.0000000000000134

M3 - Review article

VL - 2

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 4

M1 - e134

ER -